Clinical evidence provided a rationale for considering Natural ASX as a therapeutic agent against inflammatory cytokine storm and associated risks in COVID-19 infection.
Early 2020, the World Health Organization (WHO) announced the outbreak of the coronavirus disease (COVID-19). The novel species of coronavirus SARS-CoV-2 has shown to elevate the levels of inflammatory factors such as interleukin-6 (IL-6) and Tumour Necrosis Factor-alpha (TNF-α) responsible for severe complications and infections in the lungs and leading to acute respiratory distress syndrome.
Studies have presented evidence showing Natural astaxanthin (ASX) – a naturally occurring and potent carotenoid often called “The King of Antioxidants” – to prevent against oxidative damage and reduce aggravation of the inflammatory responses.
Moreover, Natural ASX has a potent Peroxisome Proliferator Activated Receptors activity (PPARs). At cellular level, PPARs control a variety of target genes involved in lipid homeostasis, diabetes, cancer, cellular intermediary metabolism, and inflammation.
Natural ASX has a strong clinically proven safety profile, proven powerful antioxidant, potent anti-inflammatory, and immunomodulatory properties. These unique features position Natural ASX as an excellent choice against inflammation and its consequences. It is plausible why researchers have speculated that ASX could be considered as a potential adjunctive supplement.
Links to more relevant studies:
